0340-7004

Cancer Immunology Immunotherapy

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 7143 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact7143 DOIs
2

Attach ORCID iDs across 6307 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact6307 DOIs
3

Deposit reference lists for 2584 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact2584 DOIs

DOIs for this ISSN

Showing the top 5 of 7598 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Elevated myeloid-derived suppressor cells in pancreatic, eso… (10.1007/s00262-011-1028-0)
Abstract ORCID License
201.70 488
2 Apoptosis pathways in cancer and cancer therapy (10.1007/s00262-003-0474-8)
Abstract References ORCID
193.40 378
3 Prognostic significance of tumor-infiltrating T-lymphocytes… (10.1007/s00262-008-0583-5)
Abstract ORCID License
188.59 326
4 Phase I trial of a multi-epitope-pulsed dendritic cell vacci… (10.1007/s00262-012-1319-0)
Abstract ORCID License
187.37 314
5 2011: the immune hallmarks of cancer (10.1007/s00262-010-0968-0)
Abstract ORCID License
187.06 311
6 A listing of human tumor antigens recognized by T cells (10.1007/s002620000169)
Abstract References ORCID
185.89 300
7 Signaling events involved in anti-CD20-induced apoptosis of… (10.1007/s002620050016)
Abstract References ORCID
185.78 299
8 Immature myeloid cells and cancer-associated immune suppress… (10.1007/s00262-002-0280-8)
Abstract References ORCID
177.83 234
9 Sipuleucel-T immune parameters correlate with survival: an a… (10.1007/s00262-012-1317-2)
Abstract ORCID License
175.83 220
10 The selection of tumor variants with altered expression of c… (10.1007/s00262-004-0517-9)
Abstract References ORCID
175.68 219
11 Immunotherapy of cancer with dendritic-cell-based vaccines (10.1007/s002620050465)
Abstract References ORCID
175.38 217
12 Results of a phase I clinical trial of vaccination of glioma… (10.1007/s002620100205)
Abstract References ORCID
174.48 211
13 Response definition criteria for ELISPOT assays revisited (10.1007/s00262-010-0875-4)
Abstract ORCID License
173.70 206
14 Presence of IgE antibodies to bovine serum albumin in a pati… (10.1007/s002620050614)
Abstract References ORCID
173.54 205
15 Prognostic value of the CD4+/CD8+ ratio of tumour infiltrati… (10.1007/s00262-003-0388-5)
Abstract References ORCID
170.56 187
16 Role of IL-13 in regulation of anti-tumor immunity and tumor… (10.1007/s00262-003-0445-0)
Abstract References ORCID
169.15 179
17 Whole-cell cancer vaccination: from autologous to allogeneic… (10.1007/s00262-008-0536-z)
Abstract ORCID License
167.28 169
18 Folate targeting of haptens to cancer cell surfaces mediates… (10.1007/s00262-002-0266-6)
Abstract References ORCID
164.90 157
19 Phase I clinical trial of a recombinant canarypoxvirus (ALVA… (10.1007/s002620000146)
Abstract References ORCID
164.90 157
20 Escape from immunotherapy: possible mechanisms that influenc… (10.1007/s00262-004-0540-x)
Abstract References ORCID
164.48 155
21 Tumor-induced immune dysfunction (10.1007/s002620050586)
Abstract References ORCID
164.48 155
22 Selective tumoricidal effect of soluble proteoglucan extract… (10.1007/s002620050473)
Abstract References ORCID
164.27 154
23 Binding to CD20 by Anti-B1 Antibody or F(ab') 2 is sufficien… (10.1007/s00262-001-0247-1)
Abstract References ORCID
161.88 143
24 In acute myeloid leukemia, B7-H1 (PD-L1) protection of blast… (10.1007/s00262-010-0909-y)
Abstract ORCID License
161.88 143
25 Orally administered β-glucans enhance anti-tumor effects of… (10.1007/s00262-002-0321-3)
Abstract References ORCID
161.19 140
26 CD44v6: a target for antibody-based cancer therapy (10.1007/s00262-003-0494-4)
Abstract References ORCID
160.96 139
27 Naturally occurring B-cell responses to breast cancer (10.1007/s00262-003-0409-4)
Abstract References ORCID
160.02 135
28 Heat shock protein 70 expression induces antitumor immunity… (10.1007/s00262-002-0335-x)
Abstract References ORCID
159.53 133
29 Disregulation in TH1 and TH2 subsets of CD4 + T cells in per… (10.1007/s002620050244)
Abstract References ORCID
158.80 130
30 Innate signaling by the C-type lectin DC-SIGN dictates immun… (10.1007/s00262-008-0615-1)
Abstract ORCID License
158.55 129
31 Rapid turnover of the CD8 + CD28 - T-cell subset of effector… (10.1007/s00262-003-0395-6)
Abstract References ORCID
157.53 125
32 Maturation of monocyte-derived dendritic cells with Toll-lik… (10.1007/s00262-008-0489-2)
Abstract ORCID License
157.27 124
33 Phase 1B study to improve immune responses in head and neck… (10.1007/s00262-003-0459-7)
Abstract References ORCID
157.01 123
34 The immunological effects of taxanes (10.1007/s002620000122)
Abstract References ORCID
157.01 123
35 Signaling defects in T lymphocytes of patients with malignan… (10.1007/s002620050585)
Abstract References ORCID
156.74 122
36 In vivo antitumor effects of murine interferon- γ -inducing… (10.1007/s002620050345)
Abstract References ORCID
156.48 121
37 Macrophage infiltration in human non-small-cell lung cancer:… (10.1007/s002620050603)
Abstract References ORCID
155.67 118
38 Mucin gene (MUC1) transfected dendritic cells as vaccine: re… (10.1007/s00262-002-0317-z)
Abstract References ORCID
155.39 117
39 Clinical experience with CD64-directed immunotherapy. An ove… (10.1007/s002620050435)
Abstract References ORCID
155.11 116
40 Anti-HER2 vaccines: new prospects for breast cancer therapy (10.1007/s00262-010-0869-2)
Abstract ORCID License
154.27 113
41 Exosome-based immunotherapy (10.1007/s00262-003-0472-x)
Abstract References ORCID
153.98 112
42 The T�bingen approach: identification, selection, and valida… (10.1007/s00262-003-0480-x)
Abstract References ORCID
153.40 110
43 A p50 surface antigen restricted to human urinary bladder ca… (10.1007/bf00199769)
Abstract References ORCID
153.10 109
44 Fever and cancer in perspective (10.1007/s002620100216)
Abstract References ORCID
153.10 109
45 Effective immunotherapy against cancer (10.1007/s00262-004-0577-x)
Abstract References ORCID
152.81 108
46 Noscapine inhibits tumor growth with little toxicity to norm… (10.1007/s002620000109)
Abstract References ORCID
152.81 108
47 Anandamide is an endogenous inhibitor for the migration of t… (10.1007/s00262-004-0509-9)
Abstract References ORCID
152.51 107
48 Treatment of recurrent glioma with intracavitary alloreactiv… (10.1007/s002620050405)
Abstract References ORCID
151.90 105
49 Monoclonal antibody drug immunoconjugates for targeted treat… (10.1007/s00262-002-0352-9)
Abstract References ORCID
151.59 104
50 Dendritic cells are dysfunctional in patients with operable… (10.1007/s00262-003-0485-5)
Abstract References ORCID
151.59 104